Press Releases

Date	Title	PDF Version
Nov 29, 2023	AstraZeneca advances scientific leadership in hematology at ASH 2023
Sep 20, 2023	Alexion completes purchase and licence agreement for early-stage rare disease gene therapy portfolio from Pfizer
Sep 06, 2023	Update on US regulatory review of ULTOMIRIS® in NMOSD
Jul 28, 2023	Alexion, AstraZeneca Rare Disease, enters agreement with Pfizer to acquire a portfolio of preclinical rare disease gene therapies
Jun 09, 2023	Danicopan as add-on to ULTOMIRIS® or SOLIRIS® improved hemoglobin levels and maintained disease control in patients with PNH experiencing signs or symptoms of clinically significant extravascular hemolysis
Mar 02, 2023	Alexion advances commitment to transform patient outcomes in rare neurological diseases at AAN 2023
Nov 30, 2022	AstraZeneca showcases strength of hematology portfolio and pipeline across multiple hard-to-treat conditions at ASH 2022
Nov 16, 2022	Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeutics
Oct 27, 2022	ULTOMIRIS® (ravulizumab-cwvz) showed zero relapses in adults with neuromyelitis optica spectrum disorder (NMOSD) with median treatment duration of 73 weeks
Oct 12, 2022	Alexion aims to advance NMOSD treatment landscape with exceptional ULTOMIRIS® (ravulizumab-cwvz) efficacy data at ECTRIMS 2022

Search